CCR2 and Glucose intolerance: Moreover, treatment with PF4178903, another dual CCR2/CCR5 antagonist, reduces adipose tissue macrophage infiltration, lowers serum proinflammatory cytokines levels, and improves insulin resistance and glucose intolerance in mice fed a high-fat diet [119].